The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Houston’s life sciences real estate market is growing again — this time with a 21.3-acre mixed-use district aimed at biotech ...

The Houston-based compounding pharmacy rejected Lilly's claims of false advertising in a New Jersey federal court. © 2025 American City Business Journals. All rights ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Sarah Strauss. Bob Jones University — Oronoco: Abigail Graham. Cedarville University —: Johanna Trondson. Central Lakes College —: Johnny Tong. Concordia University —: Hope Nelson; Winona: Naa Kordai ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...